{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T18:31:28Z","timestamp":1771266688710,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"International Fibrodysplasia Ossificans Progressiva Association (IFOPA)"},{"DOI":"10.13039\/100007928","name":"Perelman School of Medicine, University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007928","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ian Cali Endowment for FOP Research"},{"DOI":"10.13039\/100013182","name":"Whitney Weldon Endowment for FOP Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013182","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ashley Martucci FOP Research Fund"},{"name":"Brinkman family"},{"name":"Isaac and Rose Nassau Professorship of Orthopaedic Molecular Medicine"},{"DOI":"10.13039\/100006920","name":"University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Radiant Hope Foundation"}],"content-domain":{"domain":["clinicalkey.jp","thebonejournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.bone.2017.07.019","type":"journal-article","created":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T17:45:31Z","timestamp":1500572731000},"page":"276-280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases"],"prefix":"10.1016","volume":"109","author":[{"given":"Frederick S.","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey R.","family":"Andolina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C.","family":"Adamson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David T.","family":"Teachey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry Z.","family":"Finklestein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David H.","family":"Ebb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Whitehead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Keen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Pignolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2017.07.019_bb0005","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.berh.2007.11.007","article-title":"Fibrodysplasia ossificans progressiva","volume":"22","author":"Kaplan","year":"2008","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.bone.2017.07.019_bb0010","series-title":"Emerging Concepts in Pediatric Bone Disease","first-page":"437","article-title":"Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons","volume":"vol. 10(S-2)","author":"Pignolo","year":"2013"},{"key":"10.1016\/j.bone.2017.07.019_bb0015","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/jbmr.2728","article-title":"The natural history of flare-ups in fibrodysplasia ossificans progressiva: a comprehensive global assessment","volume":"31","author":"Pignolo","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.07.019_bb0020","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2106\/JBJS.I.00705","article-title":"Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva","volume":"92","author":"Kaplan","year":"2010","journal-title":"J. Bone Joint Surg. Am."},{"key":"10.1016\/j.bone.2017.07.019_bb0025","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ng1783","article-title":"A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva","volume":"38","author":"Shore","year":"2006","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.bone.2017.07.019_bb0030","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/humu.20868","article-title":"Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1","volume":"30","author":"Kaplan","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bone.2017.07.019_bb0035","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1359\/jbmr.071030","article-title":"Dysregulated BMP signaling and enhanced osteogenic differentiation of connective tissue progenitor cells from patients with fibrodysplasia ossificans progressiva","volume":"23","author":"Billings","year":"2008","journal-title":"J. Bone Miner. Res."},{"issue":"11","key":"10.1016\/j.bone.2017.07.019_bb0040","first-page":"3462","article-title":"The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization","volume":"119","author":"Shen","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2017.07.019_bb0045","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cytogfr.2009.10.006","article-title":"The FOP metamorphogene encodes a novel type I receptor that dysregulates BMP signaling","volume":"20","author":"Kaplan","year":"2009","journal-title":"Cytokine Growth Factor Rev."},{"issue":"303","key":"10.1016\/j.bone.2017.07.019_bb0050","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac4358","article-title":"ACVR1(R206H) receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A","volume":"7","author":"Hatsell","year":"2005","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bone.2017.07.019_bb0055","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1510540112","article-title":"Neofunction of ACVR1 in fibrodysplasia ossificans progressiva","author":"Hino","year":"2015","journal-title":"PNAS"},{"key":"10.1016\/j.bone.2017.07.019_bb0060","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.semcdb.2015.12.013","article-title":"Granting immunity to FOP and catching heterotopic ossification in the Act","volume":"49","author":"Kaplan","year":"2016","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.bone.2017.07.019_bb0065","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/jbmr.2848","article-title":"Cellular hypoxia promotes heterotopic ossification by amplifying BMP signaling","volume":"31","author":"Wang","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.07.019_bb0070","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/21678707.2017.1304211","article-title":"Hard targets for a second skeleton: therapeutic horizons for fibrodysplasia ossificans progressiva (FOP)","volume":"5","author":"Kaplan","year":"2017","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.bone.2017.07.019_bb0075","first-page":"1","volume":"4","year":"2011","journal-title":"Clin. Proc. Intl. Clin. Consort FOP"},{"key":"10.1016\/j.bone.2017.07.019_bb0080","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd839","article-title":"Glivec (STI571, Imatinib), a rationally developed, targeted anticancer drug","volume":"1","author":"Capdeville","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bone.2017.07.019_bb0085","doi-asserted-by":"crossref","unstructured":"Iqbal N & Iqbal N. Imatinib: a breakthrough of targeted therapy in cancer. Chemother. Res. Pract. Volume 2014, 357027, 9 pages. http:\/\/dx.doi.org\/10.1155\/2014\/357027","DOI":"10.1155\/2014\/357027"},{"key":"10.1016\/j.bone.2017.07.019_bb0090","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2017.07.019_bb0095","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"Abl protein-tyrosine kinase inhibitor ST1571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"JPET"},{"key":"10.1016\/j.bone.2017.07.019_bb0100","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","article-title":"Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor","volume":"96","author":"Heinrich","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bone.2017.07.019_bb0105","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/1872213X113079990021","article-title":"Imatinib mesylate: an innovation in treatment of autoimmune diseases","volume":"3","author":"Azizi","year":"2013","journal-title":"Recent Patents Inflamm. Allergy Drug Discov."},{"key":"10.1016\/j.bone.2017.07.019_bb0110","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1136\/ard.2004.029835","article-title":"Inhibition of c-kit tyrosine kinase by Imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis","volume":"64","author":"Juurikivi","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bone.2017.07.019_bb0115","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3109\/09546634.2013.802274","article-title":"Role of Imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report","volume":"6","author":"Agarwala","year":"2013","journal-title":"J. Dermatol. Treat."},{"key":"10.1016\/j.bone.2017.07.019_bb0120","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","article-title":"Imatinib for systemic mast cell disease","volume":"362","author":"Pardanani","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2017.07.019_bb0125","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis","volume":"33","author":"Vega-Ruiz","year":"2009","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bone.2017.07.019_bb0130","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1056\/NEJMoa1613125","article-title":"KIT inhibition by imatinib in patients with severe refractory asthma","volume":"376","author":"Cahill","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2017.07.019_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-642-54490-3_1","article-title":"Imatinib mesylate","volume":"201","author":"Waller","year":"2014","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.bone.2017.07.019_bb0140","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00774-011-0323-3","article-title":"Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro","volume":"30","author":"J\u00f6nsson","year":"2012","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2017.07.019_bb0145","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.nmd.2012.10.025","article-title":"Imatinib attenuates severe mouse dystrophy and inhibits proliferation and fibrosis-marker expression in muscle mesenchymal progenitors","volume":"23","author":"Ito","year":"2013","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.bone.2017.07.019_bb0150","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1053\/hupa.2001.26464","article-title":"Mast cell involvement in fibrodysplasia ossificans progressiva","volume":"32","author":"Gannon","year":"2001","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bone.2017.07.019_bb0155","unstructured":"Convente MR, Chakkalakal SA, Yang E, Caron RJ, Zhang D, Kambayashi T, Kaplan FS, Shore EM. Depletion of mast cells and macrophages impairs heterotopic ossification in an ACVR1R206H mouse model of fibrodysplasia ossificans progressiva. (under review)."},{"key":"10.1016\/j.bone.2017.07.019_bb0160","article-title":"Surgical excision of heterotopic ossification leads to re-emergence of mesenchymal stem cell populations responsible for recurrence","author":"Agarwal","year":"2016","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.bone.2017.07.019_bb0165","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/jbmr.1562","article-title":"Multipotent progenitors resident in the skeletal muscle interstitium exhibit robust BMP-dependent osteogenic activity and mediate heterotopic ossification","volume":"27","author":"Wosczyna","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.07.019_bb0170","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/jor.23216","article-title":"Location-dependent heterotopic ossification in the rat model: the role of activated matrix metalloproteinase 9","volume":"34","author":"Davis","year":"2016","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.bone.2017.07.019_bb0175","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11420-013-9335-y","article-title":"Use of imatinib in prevention of heterotopic ossification","volume":"9","author":"Werner","year":"2013","journal-title":"HSSJ"},{"key":"10.1016\/j.bone.2017.07.019_bb0180","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nature20160","article-title":"Intronic polyadenylation of PDGFR\u03b1 in resident stem cells attenuates muscle fibrosis","volume":"540","author":"Mueller","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bone.2017.07.019_bb0185","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3171\/PED-08\/01\/091","article-title":"Lumbar puncture and surgical intervention in a child with undiagnosed fibrodysplasia ossificans progressiva","volume":"1","author":"Zaghloul","year":"2008","journal-title":"J. Neursurg. Pediatr."},{"key":"10.1016\/j.bone.2017.07.019_bb0190","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1200\/JCO.2008.21.2514","article-title":"Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study","volume":"27","author":"Schultz","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bone.2017.07.019_bb0195","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1056\/NEJMra1510061","article-title":"Adaptive designs for clinical trials","volume":"375","author":"Bhatt","year":"2016","journal-title":"N. Engl. J. Med."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328217302454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328217302454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T16:52:30Z","timestamp":1750783950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328217302454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":39,"alternative-id":["S8756328217302454"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2017.07.019","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2017.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}